cPLA2 (phospho-S505) polyclonal antibody 
Datasheet
COA
MSDS
SHIP
Product Name :
cPLA2 (phospho-S505) polyclonal antibody Background :
Phospholipase A2s (PLA2s) constitute a family of esterases that hydrolyze the sn-2-acyl ester bond in glycerophospholipid molecules. These enzymes are generally calcium-dependent and have been found both intra- and extracellularly. By hydrolyzing the sn-2 bond in glycerophospholipids, PLA2s release fatty acids. One such fatty acid, arachidonic acid, generates the substrates for the initiation of the arachidonic acid cascade that produces various eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes), many of which are potent mediators of inflammation. PLA2s include both the relatively low molecular weight type I and type II enzymes and the form known as cytoplasmic PLA2 (cPLA2). cPLA2 is present in the cytosol of various cells and tissues including platelets, macrophages and monoblasts; and preferentially hydrolyzes the sn-2 position of phospholipid molecules, releasing free arachidonate. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
p-cPLA2 (S505) polyclonal antibody detects endogenous levels of cPLA2 protein only when phosphorylated at Ser505. Immunogen :
Synthetic phosphopeptide derived from human cPLA2 around the phosphorylation site of Serine 505. Conjugate :
Unconjugated Modification :
Phosphorylation
cPLA2 (phospho-S505) polyclonal antibody Background :
Phospholipase A2s (PLA2s) constitute a family of esterases that hydrolyze the sn-2-acyl ester bond in glycerophospholipid molecules. These enzymes are generally calcium-dependent and have been found both intra- and extracellularly. By hydrolyzing the sn-2 bond in glycerophospholipids, PLA2s release fatty acids. One such fatty acid, arachidonic acid, generates the substrates for the initiation of the arachidonic acid cascade that produces various eicosanoids (i.e. prostaglandins, leukotrienes and thromboxanes), many of which are potent mediators of inflammation. PLA2s include both the relatively low molecular weight type I and type II enzymes and the form known as cytoplasmic PLA2 (cPLA2). cPLA2 is present in the cytosol of various cells and tissues including platelets, macrophages and monoblasts; and preferentially hydrolyzes the sn-2 position of phospholipid molecules, releasing free arachidonate. Product :
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
p-cPLA2 (S505) polyclonal antibody detects endogenous levels of cPLA2 protein only when phosphorylated at Ser505. Immunogen :
Synthetic phosphopeptide derived from human cPLA2 around the phosphorylation site of Serine 505. Conjugate :
Unconjugated Modification :
Phosphorylation
-
Western blot (WB) analysis of p-cPLA2 (S505) pAb at 1:500 dilution Lane1:MCF-7 whole cell lysate(40ug) Lane2:A549 whole cell lysate(40ug) Lane3:The Uterus tissue lysate of Rat(40ug) Lane4:The Uterus tissue lysate of Mouse(40ug) Lane5:3T3-L1 whole cell lysate(40ug) -
Immunohistochemistry (IHC) analyzes of p-cPLA2 (S505) pAb in paraffin-embedded human breast cancer tissue.
Diosgenin inhibits superoxide generation in FMLP-activated mouse neutrophils via multiple pathways
PMCID: Pubmed No.:25246240
Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway
PMCID: Pubmed No.:26134424
Diosgenin inhibits superoxide generation in FMLP-activated mouse neutrophils via multiple pathways
PMCID: Pubmed No.:25246240
Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway
PMCID: Pubmed No.:26134424
UCN enhances TGF-beta-mediated mitoinhibition of VSMCs via counteracting TGF-beta-induced cPLA2 expression and activation
PMCID: Pubmed No.:27702653
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide（0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.